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ABSTRACT
Chronic kidney disease (CKD) is highly prevalent in several countries and is associated with the incidence 
of end-stage renal disease (ESRD) and also with premature morbidity and mortality, especially from 
cardiovascular origin. However, efficient treatments have existed for two decades but have not led to 
major decrease in either ESRD incidence or premature death of CKD patients. Some authors suggested 
that the deliverance of suboptimal care can explain, at least partly, these disappointing findings. Several 
observational studies support this idea by showing that some recommended medications are under-
prescribed in CKD patients, and that some patients are sometimes insufficiently monitored for clinical and 
biological parameters. Therefore, new models of renal care deliverance have been developed, trying to 
optimise patient treatment with the hope that it could positively impact their outcomes. In this article, we 
will focus on the multidisciplinary clinic and the renal care network models and we will review the results of 
the main studies that sought to test the impact of these new structures on patient’s prognosis. Although 
most of these studies are observational, they predominantly show a positive effect on renal prognosis and 
also survival. However, the only one randomised clinical trial with long-term follow-up failed to find any 
positive effect despite increased cost. Therefore, more evidence, based on results of randomised clinical 
trials, is needed before a wide implementation of this kind of program.
Keywords: Chronic kidney disease, quality of care, multidisciplinary care model, renal care network.
INTRODUCTION
Chronic kidney disease (CKD) is an increasingly 
prevalent progressive disease that ultimately leads 
to the requirement of chronic renal replacement 
therapy (RRT). This treatment is associated with 
high morbidity and mortality and a significant 
reduction in the quality of life for patients. 
Furthermore, this is an expensive care that has to 
be supported by the health care system. Therefore, 
the prevention of the progression to end-stage renal 
disease (ESRD) and of the premature deaths of 
CKD patients is of paramount importance and has 
become a public health issue.1 Clinical studies have 
been led to find an efficient treatment to improve 
CKD patient prognosis.2,3 Nevertheless, there has 
been no significant decrease in the incidence of 
ESRD in developed countries over the last 10 years.4,5 
Moreover, even if the mortality rate of non-dialysis 
CKD patients tends to decrease, it remains higher 
comparatively to non-CKD patients in the USA.4 
Although several factors may be involved, some 
authors emphasise the role played by suboptimal 
care delivered to CKD patients.6 The inappropriate 
coordination of care, the lack of communication 
between the healthcare professionals (HP), and 
a certain degree of therapeutic inertia might 
explain the deliverance of suboptimal care.6,7 This 
has led nephrologists to question how to provide 
multidisciplinary care in an efficient way to CKD 
patients. In this process, two different models have 
emerged: the multidisciplinary clinic (MDC) and the 
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we will focus first on the recent Kidney Diseases 
Improving Global Outcomes (KDIGO) guidelines8 
about non-dialysis CKD management and then on 
the results of studies that sought to evaluate the 
quality of care received by CKD patients. We also 
focus on other studies which have found a link 
between this quality of care and patient prognosis. 
Finally, we will talk about the results of studies that 
aimed to test the impact of MDC or RCN on CKD 
patient outcomes.
What Do the KDIGO Guidelines Tell Us About 
Nephrologist Referral and the Model of Care?
The most recent clinical guidelines about the 
evaluation and management of CKD came from the 
KDIGO foundation and were published in January 
2013.8 An entire chapter has been dedicated to the 
clinical situations justifying a specialist consultation. 
Additionally, in this chapter some recommendations 
have been made about the model of care that should 
be used to optimally treat patients with progressive 
CKD. Amongst the situations that should lead to a 
nephrologist consultation we find the occurrence 
of acute kidney injury or of a rapid decrease of     
glomerular filtration rate (GFR), the progressive   
nature of CKD or the existence of a persisting 
proteinuria or haematuria. Regarding the level of 
estimated GFR (eGFR) which justifies specialist 
referral, irrespective of the presence of other factors, 
the work group advises an eGFR of less than 30 ml/
min per 1.73 m2. The level of evidence assigned to 
these guidelines is moderate. Moreover, the work 
group stresses the importance of evaluating the risk 
of requiring renal replacement therapy in the next 
12 months for patients with progressive CKD, and in 
cases of a risk above 10-20%, they recommend referral 
of the patients. The level of evidence is moderate for 
this recommendation and relies on several studies 
and two meta-analyses. The benefits of timely 
referral of patients for preparing RRT are based on 
mortality (the 1 year mortality was decreased by more 
than 50%), morbidity (shorter length of stays in the 
hospital) and on the cost of the care. Finally, the work 
group also suggest that patients with progressive 
CKD should be managed in multidisciplinary care 
framework (level of evidence moderate) with access 
to dietary counselling, education, and psychological 
and social care. However, they did not suggest any 
particular model that would be the most suitable 
for reaching care appropriateness and state that the 
implementation of this structure may be customised 
to specific circumstances. As a conclusion, it can be 
said that these recommendations clearly express the 
clinical situations requiring a nephrologist referral, 
emphasise the crucial matter of the timely referral of 
patients with progressive CKD, and underline, for the 
first time, the importance of multidisciplinary care 
to reach the clinical targets enabling to ameliorate 
patient outcomes.    
Care of CKD Patients Could Be Optimised
Several studies showed that care for CKD patients 
could be optimised. Kausz et al.9 showed, in an 
observational study of 600 patients with average 
eGFR of 22.2 ml/min/1.73 m2, that both the frequency 
of biological parameters monitoring and of 
recommended therapeutic agents prescription were 
low in CKD patients. These findings were associated 
with a low proportion of patients achieving 
targets for the control of anaemia and calcium/
phosphate disorders. In another large sample of 
American patients with moderate to severe CKD, 
Nissenson et al.10 found that the prevalence of 
patients with an angiotensin-converting-enzyme 
inhibitor (ACEI) prescription ranged from 5% to 
59% (although the proportion of CKD patients in 
USA with hypertension is 74% according to the US 
renal data system (USRDS) report).5 Interestingly, 
there were no differences in ACEI prescription rates 
between patients who visited a nephrologist and 
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Figure 1. Multidisciplinary care model for chronic 
kidney disease patients. Arrows represent the 
interaction between the healthcare professionals 
and the patient.those who did not. Finally, they also found a low 
prevalence of Erythropoietin (EPO) prescription 
(7.4%) despite 36.2% of patients with haematocrit 
below 33%.10 When we focus on the cardioprotective 
treatments prescription in CKD patients, the rate of 
prescription of this kind of treatments is also low. 
In a Canadian study, which included 304 patients 
with creatinine clearance <75 ml/min, the authors 
focused on the prescription rate of cardioprotective 
treatments. They found that cardiovascular disease 
(CVD) history was present in 38.5% of the patients 
and that several cardiovascular risk factors were 
highly prevalent (hypertension 80%, diabetes 37.5%, 
hyperlipidemia 43.4%). Nevertheless, they also 
found a low prescription rate of aspirin (45.3%), 
renin-angiotensin system (RAS) blocker (63.2%) and 
beta-blocker (50.4%). Moreover, among patients 
with known hyperlipidaemia, statin was prescribed 
in only 49%.11 Taken together, these results suggest 
that the care of CKD patients could be improved at 
several levels: monitoring of biological parameters, 
renoprotective and cardioprotective treatments, and 
treatment of the metabolic complications of CKD.
Beside data about the care of the general population 
of the CKD patients, some investigators have 
studied specific populations at increased risk of 
adverse outcomes. Kausz et al.12 studied the issue of 
care adequacy in a subset population of American 
patients aged over 67 years. In this study, the 
authors found that a low proportion of diabetic 
patients with CKD had been tested for HbA1c assay 
or fundus examination during the two year period 
before dialysis started (75% and 60% respectively). 
In addition, the proportion of CKD patients having 
been properly tested for anaemia condition (iron 
studies and research of occult blood in stool) and 
parathyroid hormone (PTH) was low (less than 50% 
and 15%, respectively), with an even lower proportion 
in the population of patients subsequently treated by 
haemodialysis. Lastly, the results of this study show 
that CKD patients were less frequently screened 
for cancer and were also less likely to receive some 
immunisations, despite a more frequent monitoring 
for hyperlipidaemia and heart conditions. 
Several studies have also focused on the care delivered 
to CKD patients with heart failure (HF), a population 
that raises particular concern due to a growing 
prevalence of HF in American CKD patients, and a 
high mortality rate.5 Furthermore, this population 
is also of interest because the prescription of some 
medications is recommended by both the guidelines 
for treatment of CKD and those for HF treatment 
(leading to expectation of a higher prescription 
rate of these treatments). In 2004, Ezekowitz et 
al.13 analysed data from the Canadian prospective 
cohort APPROACH (6,427 patients with HF and with 
coronary artery disease ascertained by angiographic 
sutdy) in which 39% of the patients had creatinine 
clearance below 60 ml/min. The comparison of three 
groups categorised according to the level of eGFR 
(>60 ml/min, between 30 and 60 and <30 ml/min) 
showed that the proportion of patients receiving 
aspirin or other antiplatelet agents, beta-blockers, 
RAS blockers and statins lowered as renal function 
decreased. In patients with eGFR below 30 ml/min, 
the prescription rates of aspirin, beta-blockers, and 
RAS blockers were respectively 67%, 52% and 52%. 
In another Canadian cohort of patients with CKD 
and HF, McAlister et al.14 also showed that the CKD 
patients were less frequently treated with certain 
therapeutic agents like ACEI, beta-blockers and 
spironolactone while they were receiving diuretics 
more often. The rate of prescription of RAS blockers 
and beta-blockers were respectively 75% and 34% 
in patients with CKD stage 4 or 5 while it was 
92% and 57% in patients with eGFR >90 ml/min.14 
Taken together, these findings suggest that the 
prescription rate of some pivotal drugs for HF and 
CKD treatment, like ACEI, are quite low. In addition, 
other recommended types of drugs are probably 
under-prescribed as well. Therefore, it is likely that 
patients with both CKD and HF are more prone to 
suboptimal treatments. Thus, there is an opportunity 
for improvement that could possibly lead to less 
morbidity and mortality in these patients. 
Impact of the Quality of Care on Patient 
Outcomes
The first step in order to improve outcomes of patients 
with advanced CKD seems to be the referral to a 
nephrology consultation. This is especially justified 
in the 1 to 2 year period before starting dialysis, when 
patients request adequate preparation for dialysis 
treatment. It is well known that late referral of patients 
leads to start acutely RRT, which is largely detrimental 
for early outcomes in dialysis.6 The importance of 
the nephrologist visit has been underlined by two 
large observational and retrospective studies from 
the DOPPS that showed a 35% decrease of patient 
mortality during the first 4 months of dialysis 
treatment in patient groups that have been followed 
by a nephrologist15 and a 43% decrease of mortality 
in the first year.16 In patients with less severe CKD, 
Jones et al.17 showed that nephrology referral 
allowed a decrease in the renal disease progression 
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improvement in patient survival over a 1 year period. 
However, if we refer to some results of previously 
cited studies about CKD patient care, some further 
improvement  seems  possible,  even  in  the  case  of  a                                                         
nephrologist follow-up.
In France, Thilly et al.18 conducted the AVENIR study, 
which aimed specifically to study the impact of 
pre-dialysis care on early patient outcomes after 
dialysis start. In one published report, they showed 
that physicians failed to reach recommended blood 
pressure and proteinuria level in a high proportion 
of CKD patients in the year before starting dialysis 
(respectively 75% and 85%) and that this result was 
not modified when the patients had been followed-
up by a nephrologist. Although there was more 
intensive treatment of patients when a nephrologist 
followed them, the lack of differences can be 
explained by a trend to preferentially address the 
most severe patients to a nephrologist. In another 
study, this team aimed to describe the proportion of 
patients reaching the clinical target for the control 
of the metabolic complications linked to CKD. 
The clinical objectives were achieved in a variable 
proportion of cases, sometimes low (16.7% to 72.4% 
depending on parameters considered) and 12.2% of 
the patients have been considered as receiving low 
quality care. In addition, the authors showed a low 
prescription rate of some medications (vitamin D, 
bicarbonates, statins) that has probably contributed 
to the previous findings. Even more interesting was 
their observation that, after adjustment, the quality 
of care and the number of nephrology consultations 
were positively related.19 Finally, they have recently 
shown that the quality of care was also positively 
related to the patient’s 1 year survival on dialysis.20 
Taken together, these results show the impact of 
the care provided by the nephrologist (that could 
theoretically lead to better survival) and suggest 
that the quality of care could be related to the 
number of nephrology consultations. Interestingly, 
this research group also found that the quality of 
care and the time since referral to a nephrologist 
can independently impact the quality of life (QoL) 
of patients at dialysis onset.21 This is an important 
finding because it is known that the QoL of patients 
with severe CKD is greatly impaired22 and that few 
interventions are available to improve it. 
Two Models of Multidisciplinary and 
Coordinated Care to Improve the Prognostic 
of CKD Patients
The first model is generally called multidisciplinary 
clinic (MDC), but also can be named ‘low-clearance 
clinic’. In this model, every kind of HP involved 
in the treatment of CKD patients is in the same 
place (nephrologists, dieticians, nurses, pharmacist 
etc.). MDC is commonly intended for patients with 
advanced CKD that require enhanced monitoring 
with quite frequent consultations. Because of its 
multidisciplinary nature, this type of structure 
allows a theoretically appropriate coordination of 
the different treatments, leading to optimal care for 
patients (Figure 1). In theory, MDC can also provide 
educational sessions that allow enhancement of 
patient understanding of their disease in order to 
motivate them and help to improve QoL. The second 
model is called renal care network (RCN), which is 
a care network dedicated to the treatment of CKD 
patients. Compared to the MDC, which centralises 
care in the same location, RCN allows more ‘flared’ 
care, favouring the maintenance of ambulatory 
links with HP located outside of the hospital. The 
communication and coordination between HP are 
provided by the availability of electronically-shared 
medical records and a dedicated coordination 
staff (Figure 2).23 As in the MDC, RCN can deliver 
education to the patients.
Several investigators in different countries have 
tested the clinical efficacy of MDC and RCN on the 
outcomes of CKD patients (Table 1). The studies 
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Figure 2. Renal care network model for chronic 
kidney disease patients. We can note the existence 
of a structure dedicated to the care coordination and 
the manifold interactions between the healthcare 
professionals and the patient.NEPHROLOGY  •  July 2013    EMJ EUROPEAN MEDICAL JOURNAL 64
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Table 1. Studies that have assessed the effect of multidisciplinary clinic (MDC) or renal care network 
(RCN) on outcomes of patients with chronic kidney disease (CKD).are mainly observational and retrospective and, 
so far, just two randomised controlled trials (RCT) 
have been reported in the field.24,25 Moreover, some 
studies included patients with severe CKD and were 
interested in the outcomes of patients in the early 
dialysis period, though others included patients with 
less advanced CKD and evaluated mainly the effect 
on CKD progression (Table 1).24,26-31 The first study 
by Harris et al.24 was a RCT including 437 patients 
with mean eGFR of 34 ml/min. The authors found no 
differences between the two groups after a follow-
up of 5 years, even with an important increase 
of the cost of patient care due to more frequent 
consultations. The second, by Hotu et al.25 was 
positive for progression of CKD in diabetic patients 
but the intervention, although close to the RCN 
model, was pretty atypical and the follow-up was of 
1 year only. 
Other studies were observational, with some including 
prospective follow-up. The follow-up duration was 
generally short, leading some authors to question 
the long-term benefit of the MDC.32 However, it 
may be noted that even an unsustainable effect is 
not without interest for the patients, particularly 
for care delivered in the predialysis period. It seems 
likely that some studies have looked at the impact 
of optimised care of the patients during this period 
because of their potentially important impact on 
patients’ subsequent outcomes.28,29,31
The studies were mainly positive for primary 
outcome, including one with the longest follow-
up, which showed a 50% decrease of all-cause 
mortality in Canadian patients aged 66 years or 
more and presenting mainly stage 4 CKD.30 Three 
studies showed a positive effect on mortality during 
early dialysis period28,29,31 while another showed 
a positive effect on CKD progression in patients 
with less severe CKD.27 An interesting study is the 
one by Jones et al.33 that tested the effect of a RCN 
without nephrology consultation (but with remote 
management by a nephrologist) on the outcomes 
of CKD patients with a less severe health condition 
otherwise. The authors showed that around 30% of 
CKD patients referred to the nephrology department 
can be managed appropriately on a period of three 
years, with a hazard ratio for death reduced by 36% 
in the RCN group (however, largely explained by 
the initial selection of patients).33 Finally, our recent 
study is, to our knowledge, the only one that tested 
the impact of a true RCN on patient outcomes 
during the early dialysis period. Although the main 
outcome was not different between the two groups, 
we found a positive effect on several secondary 
endpoints, including CKD progression and the rate 
of hospitalisation per patient during the 1 year before 
and the year after dialysis started.23
LIMITATIONS
Although the results of most of these studies are 
positive, it should be considered that there are some 
limitations that prevent unequivocal conclusions 
about the effect of MDC and RCN. In addition to 
the short follow-up of most of these studies, just 
two studies are RCT and the evidence brought only 
by observational studies is weaker because of the 
presence of potential confounders. Another clinical 
trial by Devins et al.34 was not included in this review 
because of the intervention that was not really 
multidisciplinary (i.e. involving HP like dieticians, 
nurses, etc.) and was mainly based on psycho-
educational care which is beyond the scope of this 
review, even if education of the patients is part of the 
MDC intervention.34 
Another limit that has been mentioned by Van 
Biesen et al.32 is that the patients were included 
in the MDC on a voluntary basis in several studies. 
As such, we can suppose this has created a bias in 
their results because these patients are probably 
more implicated and motivated in their care. Thus, 
Van Biesen et al.32 underlined the potential effect 
of this bias on the impact of educational sessions: 
because these sessions are more likely to benefit 
well-motivated patients, that could have artificially 
increased the true effect of MDC (and therefore 
preclude its generalisability). Another drawback 
of this selection bias is the possible inclusion of 
patients who are more compliant about treatment 
and dietetic in the treated group. However, if this 
potential selection bias could explain a part of the 
positive effect associated with MDC or RCN, it is also 
probable that optimised care exerts a positive effect 
through others factors like prevention of iatrogeny 
and better vascular access management. Finally, 
another limitation is the lack of data regarding 
cost-effectiveness of such interventions. To our 
knowledge, there is no study on this issue and this 
should be requested before considering a large-
scale implementation.
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